The major goals of this proposal are to establish a series of immortalized cultures from normal, smoke damaged and premalignant bronchial epithelia that retain their genetic and morphologic characteristics, to characterize the cells for their DNA, RNA and protein profiles, to utilize these tools to identify genes that are both up and down regulated during multistage pathogenesis, and to use our findings to identify and validate markers for early lung cancer diagnosis and risk assessment.
In Aim 1 we will utilize a novel methodology to immortalize bronchial epithelial cells without the use of oncoproteins. We will immortalize about 20 cultures from never, former and current smokers and smokers with cancer. Some will be paired with corresponding tumor cultures. Lymphoblastoid cultures will be established as sources of constitutional DNA.
In Aim 2 we will fully characterize our cells using conventional, novel and high throughput technologies, including identification of the differentiation/premalignant state of the cells using organotypic and subrenal capsule assays, microarrays for gene expression and a very high density array comparative genomic hybridization methodology to identify up and down regulated genes. We will use genetic immunization to produce antibodies for detection of over expressed genes and develop methylation assays for under expressed genes.
In aim 4 we will validate these assays in tumors, tissues and sera of patients at increased risk and with lung cancer. This project represents a collaborative effort of scientists and clinicians at UT Southwestern Medical Center, MD Anderson Cancer Center, and the British Columbia Cancer Agency. We will utilize the considerable resources gathered by our Texas SPORE in Lung Cancer grant. We will freely share our reagents and data with other EDRN scientists. Our proposal will generate unique reagents useful for many studies, identify the sequential molecular changes during multistage pathogenesis and validate markers for early detection and risk assessment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA084971-10
Application #
7483278
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (O1))
Program Officer
Krueger, Karl E
Project Start
1999-09-30
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2010-07-31
Support Year
10
Fiscal Year
2008
Total Cost
$419,268
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Pathology
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Zhang, Yu-An; Ma, Xiaotu; Sathe, Adwait et al. (2016) Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers. J Thorac Oncol 11:346-360
Wilson, I M; Vucic, E A; Enfield, K S S et al. (2014) EYA4 is inactivated biallelically at a high frequency in sporadic lung cancer and is associated with familial lung cancer risk. Oncogene 33:4464-73
Thu, Kelsie L; Chari, Raj; Lockwood, William W et al. (2011) miR-101 DNA copy loss is a prominent subtype specific event in lung cancer. J Thorac Oncol 6:1594-8
Gibb, Ewan A; Brown, Carolyn J; Lam, Wan L (2011) The functional role of long non-coding RNA in human carcinomas. Mol Cancer 10:38
Thu, Kelsie L; Pikor, Larissa A; Chari, Raj et al. (2011) Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J Thorac Oncol 6:1521-9
Zhang, Yu-An; Maitra, Anirban; Hsieh, Jer-Tsong et al. (2011) Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. Cancer Biol Ther 12:617-28
Starczynowski, Daniel T; Lockwood, William W; Deléhouzée, Sophie et al. (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-?B pathways in human lung cancer. J Clin Invest 121:4095-105
Chari, Raj; Thu, Kelsie L; Wilson, Ian M et al. (2010) Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer. Cancer Metastasis Rev 29:73-93
Kim, Y H; Kwei, K A; Girard, L et al. (2010) Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene 29:1421-30
Gazdar, Adi F; Gao, Boning; Minna, John D (2010) Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer 68:309-18

Showing the most recent 10 out of 70 publications